From Wikipedia, the free encyclopedia
Chemical compound
ZED1227
|
|
Legal status |
|
---|
|
Methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(1-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate
|
PubChem
CID | |
---|
|
Formula | C26H36N6O6 |
---|
Molar mass | 528.610 g·mol−1 |
---|
ZED1227 is a
transglutaminase 2 (TG2) inhibitor developed by Zedira GmbH for
celiac disease
[1]
[2] and
nonalcoholic steatohepatitis.
[3]
References
-
^ Schuppan, Detlef; Mäki, Markku; Lundin, Knut E.A.; Isola, Jorma; Friesing-Sosnik, Tina; Taavela, Juha; Popp, Alina; Koskenpato, Jari; Langhorst, Jost; Hovde, Øistein; Lähdeaho, Marja-Leena; Fusco, Stefano; Schumann, Michael; Török, Helga P.; Kupcinskas, Juozas; Zopf, Yurdagül; Lohse, Ansgar W.; Scheinin, Mika; Kull, Karin; Biedermann, Luc; Byrnes, Valerie; Stallmach, Andreas; Jahnsen, Jørgen; Zeitz, Jonas; Mohrbacher, Ralf; Greinwald, Roland (1 July 2021).
"A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease". New England Journal of Medicine. 385 (1): 35–45.
doi:
10.1056/NEJMoa2032441.
hdl:
10852/92293.
PMID
34192430.
S2CID
235697132.
-
^ Büchold, Christian; Hils, Martin; Gerlach, Uwe; Weber, Johannes; Pelzer, Christiane; Heil, Andreas; Aeschlimann, Daniel; Pasternack, Ralf (17 May 2022).
"Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease". Cells. 11 (10): 1667.
doi:
10.3390/cells11101667.
PMC
9139979.
PMID
35626704.
-
^
"CTG Labs - NCBI". clinicaltrials.gov. Retrieved 3 December 2023.